Joshua M. Staley

733 total citations
18 papers, 294 citations indexed

About

Joshua M. Staley is a scholar working on Oncology, Cancer Research and Pathology and Forensic Medicine. According to data from OpenAlex, Joshua M. Staley has authored 18 papers receiving a total of 294 indexed citations (citations by other indexed papers that have themselves been cited), including 9 papers in Oncology, 9 papers in Cancer Research and 3 papers in Pathology and Forensic Medicine. Recurrent topics in Joshua M. Staley's work include Cancer Immunotherapy and Biomarkers (6 papers), Breast Cancer Treatment Studies (5 papers) and Cancer Genomics and Diagnostics (5 papers). Joshua M. Staley is often cited by papers focused on Cancer Immunotherapy and Biomarkers (6 papers), Breast Cancer Treatment Studies (5 papers) and Cancer Genomics and Diagnostics (5 papers). Joshua M. Staley collaborates with scholars based in United States, Australia and Belgium. Joshua M. Staley's co-authors include Suresh Muknahallipatna, Howard L. Johnson, Jill P. Morford, Andrew K. Godwin, Lauren Nye, Rachel Yoder, Qamar J. Khan, Anne O’Dea, Priyanka Sharma and Shane R. Stecklein and has published in prestigious journals such as Journal of Clinical Oncology, Cancer Research and Scientific Reports.

In The Last Decade

Joshua M. Staley

15 papers receiving 272 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Joshua M. Staley United States 7 124 69 64 43 40 18 294
Rajeev Pandey United States 10 57 0.5× 80 1.2× 15 0.2× 13 0.3× 41 1.0× 24 326
Kevin Thai United States 9 55 0.4× 35 0.5× 24 0.4× 22 0.5× 22 0.6× 18 449
Yu-Hsien Lee Taiwan 10 33 0.3× 59 0.9× 9 0.1× 6 0.1× 9 0.2× 30 334
Mengya Gao China 7 14 0.1× 35 0.5× 3 0.0× 5 0.1× 19 0.5× 18 220
Maja Jensen Sweden 8 18 0.1× 30 0.4× 4 0.1× 17 0.4× 16 0.4× 19 387
Han Tang China 10 56 0.5× 24 0.3× 33 0.5× 14 0.3× 32 341
Yingnan Cui China 10 29 0.2× 30 0.4× 33 0.5× 17 0.4× 27 305
Stéphanie Giraud France 10 43 0.3× 21 0.3× 4 0.1× 19 0.5× 19 307
Kuan-Yin Chen Taiwan 9 34 0.3× 5 0.1× 81 1.3× 5 0.1× 13 288

Countries citing papers authored by Joshua M. Staley

Since Specialization
Citations

This map shows the geographic impact of Joshua M. Staley's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Joshua M. Staley with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Joshua M. Staley more than expected).

Fields of papers citing papers by Joshua M. Staley

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Joshua M. Staley. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Joshua M. Staley. The network helps show where Joshua M. Staley may publish in the future.

Co-authorship network of co-authors of Joshua M. Staley

This figure shows the co-authorship network connecting the top 25 collaborators of Joshua M. Staley. A scholar is included among the top collaborators of Joshua M. Staley based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Joshua M. Staley. Joshua M. Staley is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

18 of 18 papers shown
1.
Stecklein, Shane R., Roberto Salgado, Julia White, et al.. (2025). Analysis of the Radiosensitivity Index in Paired Preneoadjuvant and Postneoadjuvant Therapy Triple-Negative Breast Cancer. International Journal of Radiation Oncology*Biology*Physics. 124(3). 717–725.
2.
Sharma, Priyanka, Jaimie Heldstab, Rachel Yoder, et al.. (2025). Results of a phase I study of alpelisib and sacituzumab govitecan (SG) in patients with HER2-negative metastatic breast cancer (MBC).. Journal of Clinical Oncology. 43(16_suppl). 1094–1094.
3.
Stecklein, Shane R., Roberto Salgado, Anne O’Dea, et al.. (2024). NeoTRACT: Phase II trial of neoadjuvant tumor infiltrating lymphocyte- and response-adapted chemoimmunotherapy for triple-negative breast cancer (TNBC).. Journal of Clinical Oncology. 42(16_suppl). TPS629–TPS629. 3 indexed citations
4.
5.
Stecklein, Shane R., Devin C. Koestler, Nanda Kumar Yellapu, et al.. (2023). Extracellular vesicle-derived non-coding RNAs to predict outcome in patients with triple-negative breast cancer (TNBC) with residual disease (RD).. Journal of Clinical Oncology. 41(16_suppl). 578–578. 3 indexed citations
6.
7.
Stecklein, Shane R., Bruce F. Kimler, Rachel Yoder, et al.. (2023). ctDNA and residual cancer burden are prognostic in triple-negative breast cancer patients with residual disease. npj Breast Cancer. 9(1). 10–10. 16 indexed citations
8.
Stecklein, Shane R., Rachel Yoder, Roberto Salgado, et al.. (2023). Abstract PD1-06: Black patients with triple negative breast cancer (TNBC) have enriched stromal tumor infiltrating lymphocytes (sTILs) and receive preferential benefit from neoadjuvant immunotherapy. Cancer Research. 83(5_Supplement). PD1–6. 2 indexed citations
9.
Stecklein, Shane R., Rachel Yoder, Joshua M. Staley, et al.. (2023). Differential impact of proliferation signature on efficacy of neoadjuvant chemoimmunotherapy in sTIL-high and sTIL-low triple-negative breast cancer (TNBC): Biomarker analysis of the NeoPACT trial.. Journal of Clinical Oncology. 41(16_suppl). 507–507. 4 indexed citations
10.
Sharma, Priyanka, Shane R. Stecklein, Rachel Yoder, et al.. (2023). Clinical and Biomarker Findings of Neoadjuvant Pembrolizumab and Carboplatin Plus Docetaxel in Triple-Negative Breast Cancer. JAMA Oncology. 10(2). 227–227. 78 indexed citations
11.
Sharma, Priyanka, Shane R. Stecklein, Rachel Yoder, et al.. (2022). Clinical and biomarker results of neoadjuvant phase II study of pembrolizumab and carboplatin plus docetaxel in triple-negative breast cancer (TNBC) (NeoPACT).. Journal of Clinical Oncology. 40(16_suppl). 513–513. 37 indexed citations
12.
Sharma, Priyanka, Shane R. Stecklein, Bruce F. Kimler, et al.. (2022). Abstract P2-01-05: Impact of post-treatment ctDNA and residual cancer burden (RCB) on outcomes in patients with triple-negative breast cancer (TNBC) and residual disease. Cancer Research. 82(4_Supplement). P2–1. 2 indexed citations
13.
Sharma, Priyanka, Vandana G. Abramson, Anne O’Dea, et al.. (2021). Romidepsin (HDACi) plus cisplatin and nivolumab triplet combination in patients with metastatic triple negative breast cancer (mTNBC).. Journal of Clinical Oncology. 39(15_suppl). 1076–1076. 16 indexed citations
14.
Staley, Joshua M., et al.. (2020). Extinction of chromosomes due to specialization is a universal occurrence. Scientific Reports. 10(1). 2170–2170. 3 indexed citations
15.
Xu, Xuan, Reza Mazloom, Joshua M. Staley, et al.. (2019). Making Sense of Pharmacovigilance and Drug Adverse Event Reporting: Comparative Similarity Association Analysis Using AI Machine Learning Algorithms in Dogs and Cats. Topics in companion animal medicine. 37. 100366–100366. 15 indexed citations
16.
Staley, Joshua M., et al.. (2019). Novel Data Sharing Agreement to Accelerate Big Data Translational Research Projects in the One Health Sphere. Topics in companion animal medicine. 37. 100367–100367. 5 indexed citations
17.
Morford, Jill P., et al.. (2008). Effects of language experience on the perception of American Sign Language. Cognition. 109(1). 41–53. 43 indexed citations
18.
Staley, Joshua M., Suresh Muknahallipatna, & Howard L. Johnson. (2007). Fibre Channel based Storage Area Network Modeling using OPNET for Large Fabric Simulations: Preliminary Work. 234–236. 65 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Rajeev Pandey Breakdown of academic impact, for papers by Kevin Thai Breakdown of academic impact, for papers by Yu-Hsien Lee Breakdown of academic impact, for papers by Mengya Gao Breakdown of academic impact, for papers by Maja Jensen Breakdown of academic impact, for papers by Han Tang Breakdown of academic impact, for papers by Yingnan Cui Breakdown of academic impact, for papers by Stéphanie Giraud Breakdown of academic impact, for papers by Kuan-Yin Chen
Rankless by CCL
2026